Filing Flows › Pyxis Oncology (PYXS) › Stock forecast & fair value
Pyxis Oncology (PYXS) stock forecast and price target
Pyxis Oncology (PYXS) trades at $1.66. 9 analysts' median price target is $7.00 (+322%), from $6.00 to $19.00.
Pyxis Oncology's latest quarter
Pyxis Oncology, Q4 2025: revenue $11.0M, operating margin -165.7%, net loss $18.1M, operating cash flow −$10.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for PYXS stock?
The median of 9 analysts' 12-month targets is $7.00, +322% from $1.66; the range is $6.00 to $19.00. The average rating is strong buy.
Does Pyxis Oncology usually beat earnings estimates?
It beat the consensus EPS estimate in 40% of the quarters on record.
Is PYXS stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.